B. Riley Issues Positive Outlook for Vaxart Earnings

Vaxart, Inc. (NASDAQ:VXRT) – B. Riley lifted their Q1 2025 earnings estimates for Vaxart in a research note issued to investors on Wednesday, March 26th. B. Riley analyst M. Mamtani now anticipates that the biotechnology company will post earnings of ($0.07) per share for the quarter, up from their prior estimate of ($0.09). B. Riley has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Vaxart’s current full-year earnings is ($0.39) per share. B. Riley also issued estimates for Vaxart’s Q2 2025 earnings at ($0.08) EPS and Q3 2025 earnings at ($0.07) EPS.

Vaxart Stock Performance

Vaxart stock opened at $0.42 on Monday. Vaxart has a fifty-two week low of $0.42 and a fifty-two week high of $1.34. The stock has a fifty day moving average of $0.62 and a two-hundred day moving average of $0.69. The company has a market capitalization of $96.01 million, a price-to-earnings ratio of -1.03 and a beta of 1.69.

Vaxart (NASDAQ:VXRT) last issued its quarterly earnings data on Thursday, March 20th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.05. Vaxart had a negative return on equity of 110.46% and a negative net margin of 431.61%. The firm had revenue of $15.19 million during the quarter, compared to the consensus estimate of $15.68 million.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Graham Capital Management L.P. boosted its stake in shares of Vaxart by 155.8% during the 4th quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 32,482 shares during the last quarter. Sequoia Financial Advisors LLC boosted its position in Vaxart by 140.9% during the fourth quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 35,213 shares during the last quarter. Invesco Ltd. grew its stake in Vaxart by 48.6% in the 4th quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 24,803 shares during the period. XTX Topco Ltd raised its holdings in Vaxart by 869.3% in the 3rd quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company’s stock valued at $116,000 after acquiring an additional 122,387 shares during the last quarter. Finally, Bank of America Corp DE lifted its stake in shares of Vaxart by 10.8% during the 4th quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 17,942 shares during the period. Institutional investors and hedge funds own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.